Insmed (INSM) slips 6% as investors continue to digest failed HS trial and reposition ahead of upcoming earnings

Insmed Incorporated (INSM) is down 6.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most plausible driver is continued weakness following Insmed’s April 7, 2026 update that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) missed both primary and secondary endpoints and that the company would discontinue the HS program. With no major new company-specific announcement today, the move also looks consistent with ongoing post-news repositioning ahead of Insmed’s next earnings update in early May.

Details:

Insmed disclosed that the Phase 2b CEDAR trial in moderate-to-severe HS did not meet primary or secondary efficacy endpoints in either the 10 mg or 40 mg arms, leading the company to halt development in HS.

The HS setback may have reduced perceived longer-term optionality for brensocatib beyond bronchiectasis, prompting some investors to de-risk after the earlier pipeline disappointment.

Insmed announced it plans to release first-quarter 2026 financial results and host a conference call on May 7, 2026, which can concentrate near-term positioning and volatility into the print.

This could also be amplified by broader biotech risk-off trading and profit-taking after prior strength, though that is more speculative without a single definitive headline.

Sources:

Insmed Investor Relations, Fierce Pharma, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 120 times in the past 6 months. Of those trades, 0 have been purchases and 120 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 52 sales selling 130,888 shares for an estimated $21,068,065.
ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 7 sales selling 93,141 shares for an estimated $15,367,891.
LEO LEE has made 0 purchases and 5 sales selling 75,000 shares for an estimated $14,692,249.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 29 sales selling 80,487 shares for an estimated $14,591,148.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 16 sales selling 75,340 shares for an estimated $12,459,520.
ORLOV S NICOLE SCHAEFFER (Chief People Strategy Officer) has made 0 purchases and 4 sales selling 30,000 shares for an estimated $5,820,060.
MELVIN MD SHAROKY sold 20,000 shares for an estimated $4,100,200
ELIZABETH M ANDERSON has made 0 purchases and 2 sales selling 15,000 shares for an estimated $2,981,600.
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 4 sales selling 5,390 shares for an estimated $925,675.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$INSM Hedge Fund Activity

We have seen 382 institutional investors add shares of $INSM stock to their portfolio, and 291 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ removed 2,892,000 shares (-41.7%) from their portfolio in Q4 2025, for an estimated $503,323,680
BLACKROCK, INC. added 2,700,148 shares (+21.8%) to their portfolio in Q4 2025, for an estimated $469,933,757
CAPITAL INTERNATIONAL INVESTORS removed 2,402,182 shares (-31.8%) from their portfolio in Q4 2025, for an estimated $418,075,755
RTW INVESTMENTS, LP added 1,758,321 shares (+57.0%) to their portfolio in Q4 2025, for an estimated $306,018,186
QUBE RESEARCH & TECHNOLOGIES LTD removed 1,544,315 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $268,772,582
D. E. SHAW & CO., INC. removed 1,306,469 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $227,377,864
STATE STREET CORP added 1,217,390 shares (+30.6%) to their portfolio in Q4 2025, for an estimated $211,874,555

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
UBS issued a "Buy" rating on 01/06/2026
TD Cowen issued a "Buy" rating on 12/18/2025
Goldman Sachs issued a "Buy" rating on 12/18/2025
Wells Fargo issued a "Overweight" rating on 12/16/2025
Mizuho issued a "Outperform" rating on 12/01/2025
RBC Capital issued a "Outperform" rating on 10/31/2025

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 18 analysts offer price targets for $INSM in the last 6 months, with a median target of $216.5.

Here are some recent targets:

Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026
Leonid Timashev from RBC Capital set a target price of $216.0 on 04/14/2026
Eliana Merle from Barclays set a target price of $237.0 on 04/01/2026
Matthew Harrison from Morgan Stanley set a target price of $212.0 on 03/30/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $245.0 on 03/26/2026
Graig Suvannavejh from Mizuho set a target price of $206.0 on 03/25/2026
Benjamin Burnett from Wells Fargo set a target price of $177.0 on 03/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.